Ju-Ming Lu1, Li-Nong Ji2, Yu-Feng Li3, Quan-Min Li4, Shan-Shan Lin5, Xiao-Feng Lv6, Li Wang7, Yuan Xu8, Xiao-Hui Guo9, Qi-Yu Guo10, Li Ma11, Jin Du12, Ying-Li Chen13, Cui-Ling Zhao3, Qiu-Lan Zhang4, Qi-Mei She5, Xiu-Min Jiao6, Mei-Hua Lu7, Rong-Qing Pan8, Ying Gao9. 1. Department of Endocrinology, Chinese PLA General Hospital, Beijing, 100853, China. Electronic address: lujuming301@126.com. 2. Department of Endocrinology, Beijing, Peking University People's Hospital, Beijing 100035, China. Electronic address: jilinong@gmail.com. 3. Department of Endocrinology, Beijing, Pinggu Hospital, Beijing, 101200, China. 4. Department of Endocrinology, Beijing, The Second Artillery General Hospital of PLA, 100088, China. 5. Department of Endocrinology, Beijing, Beijing, Shijingshan Hospital, 100049, China. 6. Department of Endocrinology, General Hospital of Beijing Military Command, Beijing, 100010, China. 7. Department of Endocrinology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China. 8. Department of Endocrinology, Beijing Chaoyang Hospital of Capital Medical University, Beijing, 100023, China. 9. Department of Endocrinology, Peking University First Hospital, Beijing, 100034, China. 10. Department of Endocrinology, Navy General Hospital, Beijing, 100048, China. 11. Department of Endocrinology, Guang An Men Hospital, China Academy of Chinese Medical Science, Beijing, 102600, China. 12. Department of Endocrinology, Chinese PLA General Hospital, Beijing, 100853, China. 13. Department of Endocrinology, Beijing, Peking University People's Hospital, Beijing 100035, China.
Abstract
AIMS: This study was to determine whether serum glycated albumin (GA) was a better indicator of glycemic control than hemoglobin A1c (HbA1c) when starting a new treatment regimen for type 2 diabetes. METHODS: Newly diagnosed type 2 diabetes patients, or patients who had poor glycemic control with oral hypoglycemic agents, were enrolled at 10 hospitals in Beijing. Serum GA, HbA1c, fasting blood glucose (FBG), and C-peptide were assayed on Days 0, 14, 28, and 91 after treatment. RESULTS: Four hundred ninety-nine patients were enrolled. Mean FBG, GA and HbA1c decreased significantly in patients at Days 14, 28, and 91. In patients with improved glycemic control, the reduction of GA and HbA1c levels was 10.5±13.3% vs. 5.1±5.4% on Day 14, 16.0±13.4% vs. 9.0±7.0% on Day 28, and 18.0±16.7% vs. 18.3±9.4% on Day 91, respectively, compared with baseline values. Changes in GA on Day 14, 28 and 91 were all closely correlated with changes in HbA1c on Day 91. Change in GA on Day 14 was correlated with treatment effectiveness evaluated by HbA1c on Day 91. CONCLUSIONS: GA may be a useful marker for assessing glycemic control at an early stage of new diabetes treatment and assist in guiding adjustments to treatment and therapy.
AIMS: This study was to determine whether serum glycated albumin (GA) was a better indicator of glycemic control than hemoglobin A1c (HbA1c) when starting a new treatment regimen for type 2 diabetes. METHODS: Newly diagnosed type 2 diabetespatients, or patients who had poor glycemic control with oral hypoglycemic agents, were enrolled at 10 hospitals in Beijing. Serum GA, HbA1c, fasting blood glucose (FBG), and C-peptide were assayed on Days 0, 14, 28, and 91 after treatment. RESULTS: Four hundred ninety-nine patients were enrolled. Mean FBG, GA and HbA1c decreased significantly in patients at Days 14, 28, and 91. In patients with improved glycemic control, the reduction of GA and HbA1c levels was 10.5±13.3% vs. 5.1±5.4% on Day 14, 16.0±13.4% vs. 9.0±7.0% on Day 28, and 18.0±16.7% vs. 18.3±9.4% on Day 91, respectively, compared with baseline values. Changes in GA on Day 14, 28 and 91 were all closely correlated with changes in HbA1c on Day 91. Change in GA on Day 14 was correlated with treatment effectiveness evaluated by HbA1c on Day 91. CONCLUSIONS: GA may be a useful marker for assessing glycemic control at an early stage of new diabetes treatment and assist in guiding adjustments to treatment and therapy.